CN107810887A - 一种白斑乌贼催熟方法及专有试剂 - Google Patents
一种白斑乌贼催熟方法及专有试剂 Download PDFInfo
- Publication number
- CN107810887A CN107810887A CN201711072006.XA CN201711072006A CN107810887A CN 107810887 A CN107810887 A CN 107810887A CN 201711072006 A CN201711072006 A CN 201711072006A CN 107810887 A CN107810887 A CN 107810887A
- Authority
- CN
- China
- Prior art keywords
- ripening
- parts
- cuttlefish
- hickie
- reagent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000005070 ripening Effects 0.000 title claims abstract description 71
- 241000238371 Sepiidae Species 0.000 title claims abstract description 62
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 40
- 238000000034 method Methods 0.000 title claims abstract description 27
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims abstract description 26
- 102000009151 Luteinizing Hormone Human genes 0.000 claims abstract description 20
- 108010073521 Luteinizing Hormone Proteins 0.000 claims abstract description 20
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 108010050939 thrombocytin Proteins 0.000 claims abstract description 13
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims abstract description 12
- 238000002513 implantation Methods 0.000 claims abstract description 12
- 230000001817 pituitary effect Effects 0.000 claims abstract description 11
- 238000013268 sustained release Methods 0.000 claims abstract description 11
- 239000012730 sustained-release form Substances 0.000 claims abstract description 11
- 206010002091 Anaesthesia Diseases 0.000 claims abstract description 9
- 230000037005 anaesthesia Effects 0.000 claims abstract description 9
- 229940114079 arachidonic acid Drugs 0.000 claims abstract description 6
- 235000021342 arachidonic acid Nutrition 0.000 claims abstract description 6
- 238000007654 immersion Methods 0.000 claims abstract description 6
- 230000001954 sterilising effect Effects 0.000 claims abstract description 6
- 238000002360 preparation method Methods 0.000 claims description 19
- 208000027418 Wounds and injury Diseases 0.000 claims description 11
- 229920000642 polymer Polymers 0.000 claims description 11
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 10
- 238000010438 heat treatment Methods 0.000 claims description 10
- 206010052428 Wound Diseases 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- BJIOGJUNALELMI-UHFFFAOYSA-N isoeugenol Chemical class COC1=CC(C=CC)=CC=C1O BJIOGJUNALELMI-UHFFFAOYSA-N 0.000 claims description 6
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 5
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 5
- 229940072056 alginate Drugs 0.000 claims description 5
- 235000010443 alginic acid Nutrition 0.000 claims description 5
- 229920000615 alginic acid Polymers 0.000 claims description 5
- 229960000458 allantoin Drugs 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 5
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 5
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 5
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 5
- 210000004907 gland Anatomy 0.000 claims description 5
- 235000012907 honey Nutrition 0.000 claims description 5
- 239000013535 sea water Substances 0.000 claims description 5
- 239000002383 tung oil Substances 0.000 claims description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 4
- 229930003268 Vitamin C Natural products 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- 235000019154 vitamin C Nutrition 0.000 claims description 4
- 239000011718 vitamin C Substances 0.000 claims description 4
- IEJIGPNLZYLLBP-UHFFFAOYSA-N dimethyl carbonate Chemical compound COC(=O)OC IEJIGPNLZYLLBP-UHFFFAOYSA-N 0.000 claims description 3
- 230000029663 wound healing Effects 0.000 claims description 3
- 210000004246 corpus luteum Anatomy 0.000 claims 1
- 238000002224 dissection Methods 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 238000013270 controlled release Methods 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 abstract 1
- 239000002994 raw material Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 241001663378 Sepiella maindroni Species 0.000 description 6
- 102000002322 Egg Proteins Human genes 0.000 description 4
- 108010000912 Egg Proteins Proteins 0.000 description 4
- 238000005520 cutting process Methods 0.000 description 4
- 230000000857 drug effect Effects 0.000 description 4
- 210000004681 ovum Anatomy 0.000 description 4
- BJIOGJUNALELMI-ONEGZZNKSA-N Isoeugenol Natural products COC1=CC(\C=C\C)=CC=C1O BJIOGJUNALELMI-ONEGZZNKSA-N 0.000 description 3
- 238000009360 aquaculture Methods 0.000 description 3
- 244000144974 aquaculture Species 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- BJIOGJUNALELMI-ARJAWSKDSA-N cis-isoeugenol Chemical compound COC1=CC(\C=C/C)=CC=C1O BJIOGJUNALELMI-ARJAWSKDSA-N 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- CIWBSHSKHKDKBQ-MVHIGOERSA-N D-ascorbic acid Chemical compound OC[C@@H](O)[C@@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-MVHIGOERSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- QNLVXLJTOLHAMA-UHFFFAOYSA-N N=NC=NN.N=NC=NN.C(O)(O)=O Chemical compound N=NC=NN.N=NC=NN.C(O)(O)=O QNLVXLJTOLHAMA-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000004720 fertilization Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000017448 oviposition Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000001360 synchronised effect Effects 0.000 description 2
- 241000238366 Cephalopoda Species 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 241000237852 Mollusca Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 241001481183 Sepia latimanus Species 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- UCVQOIPQDBZRMG-UHFFFAOYSA-N [C].COC(C=1C(C(=O)OC)=CC=CC1)=O Chemical compound [C].COC(C=1C(C(=O)OC)=CC=CC1)=O UCVQOIPQDBZRMG-UHFFFAOYSA-N 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 230000033822 gland development Effects 0.000 description 1
- 230000026109 gonad development Effects 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000009364 mariculture Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K61/00—Culture of aquatic animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/80—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in fisheries management
- Y02A40/81—Aquaculture, e.g. of fish
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Environmental Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Husbandry (AREA)
- Marine Sciences & Fisheries (AREA)
- Biodiversity & Conservation Biology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一种白斑乌贼催熟方法及专有试剂,催熟方法为:将白斑乌贼进行活体浸泡麻醉;用灭菌的解剖刀剖开乌贼眼下的眼窝窦,将催熟专有试剂植入眼窝窦,采用外敷愈合剂涂覆在伤口上,使伤口愈合。催熟专有试剂为缓释包埋剂,其成分及其重量份为:血清素0.06‑0.08份、绒毛膜促性腺激素0.01‑0.012份、促黄体生成素释放素类似物0.13‑0.15份、脑垂体器提取物0.004‑0.006份、花生四烯酸0.011‑0.013份、聚乳酸‑羟基乙酸共聚物1‑2份。有益效果为:本发明催熟方法能快速催熟,安全无害,操作简单,不必再依靠其自然繁殖和产卵;催熟专有试剂具有较高的稳定性、缓释或控释性能。
Description
技术领域
本发明涉及水产养殖技术领域,尤其是涉及一种白斑乌贼催熟方法及专有试剂。
背景技术
白斑乌贼(Sepia latimanus)头足纲Cephalopoda,乌贼科Sepiidae。胴部盾形,胴长约为胴宽的2倍。胴背中央区有很多大小相间的灰白色斑,两侧具一些短的横条纹,记录最大胴长0.5m,最大体重10kg,为乌贼科中体型最大的种类,分布在西北太平洋沿岸海域,主要作业渔场在琉球群岛和中国广东沿岸海域。可鲜食和干制。白斑乌贼是近年来才得以繁育成功及增养殖开发的种类,每年头足类的增养殖需要大量的受精卵,但当前白斑乌贼繁育主要靠人工养殖条件下的自然产卵,产卵量低,每头雌体产卵量仅500多粒,且高度不同步,影响白斑乌贼规模化繁育,因此开发出有效的白斑乌贼催熟和催产方法至关重要。血清素是重要的软体动物神经递质,对软体动物的性成熟和产卵具有重要的促进作用。体内注射血清素可有效促进软体动物的快速成熟及产卵。现已发现血清素对白斑乌贼促熟和产卵具有重要的作用。
现有技术如授权公告号为CN 102919182 B的中国发明专利,公开了曼氏无针乌贼扩繁方法,属于海水养殖技术领域。其包括:1)亲本的挑选和配组;2)亲本暂养;3)收集受精卵;4)人工孵化;5)幼苗培育。上述的曼氏无针乌贼扩繁方法,设计合理,步骤简单,可操作性强,通过人工调控曼氏无针乌贼亲本投喂量、投喂时间、投喂量、繁殖条件等等,得到一批优质的受精卵,然后通过人工调控曼氏无针乌贼苗种投喂量、投喂时间、投喂量、生长条件等等,形成了稳定、批量的苗种,受精卵达到95%以上,孵化率达到92%以上,成活率达到90%以上,并且最后得到的曼氏无针乌贼产品中还有大量的微量元素,提高了营养。但是该方法属于自然繁殖,使白斑乌贼规模化繁育和养殖相对困难。
发明内容
本发明的目的之一在于提供一种能快速催熟、安全无害、操作简单的白斑乌贼催熟方法。
本发明的目的之二在于提供一种各成分能发挥相互协同作用,促使乌贼性腺发育和成熟,具有较高的药物稳定性和缓释或控释性能的白斑乌贼催熟专有试剂。
本发明针对上述技术中提到的问题,采取的技术方案为:
一种白斑乌贼催熟方法,其具体步骤为:
采集性成熟白斑乌贼成体;将白斑乌贼放入含1.7-2.0% MgCl2和0.3-0.6%异丁香酚的海水中浸泡100-120s,进行活体浸泡麻醉;用灭菌的解剖刀剖开乌贼眼下的眼窝窦,将催熟专有试剂植入眼窝窦,植入量为70-80ug/g,采用外敷愈合剂涂覆在伤口上,使伤口愈合。上述外敷愈合剂的成分及其重量份为:尿囊素18-22份、海藻酸盐3-7份、桐油0.7-1.3份份、维生素C 0.3-0.5份、蜂蜜12-15份。该方法可快速加深曼氏无针乌贼全身麻醉,使曼氏无针乌贼迅速地进入麻醉诱导期,麻醉维持时间长,降低应激性,且还有一定的镇痛效果,为视神经的破坏供了良好的条件,此外异丁香酚及其代谢物可以从血液和组织中快速排出,不会在机体内产生有毒或突变物质,该方法简单,对乌贼的伤害最小,能将乌贼快速催熟,安全无害。
一种白斑乌贼催熟专有试剂,该催熟试剂为缓释包埋剂,催熟专有试剂的成分及其重量份为:血清素0.06-0.08份、绒毛膜促性腺激素0.01-0.012份、促黄体生成素释放素类似物0.13-0.15份、脑垂体器提取物0.004-0.006份、花生四烯酸0.011-0.013份、聚乳酸-羟基乙酸共聚物1-2份。该催熟制剂各成分能发挥相互协同作用,刺激脑或者胸神经节或者其他尚未发现的组织器官释放间接性的调控卵巢发育,同时配合催熟方法,促使乌贼性腺发育和成熟,能使成熟的卵子脱离卵巢滤泡膜顺利排入卵巢腔中,但不产出体外,大大缩短繁殖周期,且能使乌贼的雌雄鱼同步成熟,产卵排精,卵子和精子质量好,提高受精率和受精率的成活率。
一种白斑乌贼催熟专有试剂,其制备方法为:
核心制备:将血清素、绒毛膜促性腺激素、促黄体生成素释放素类似物、鱼性腺提取物、脑垂体器提取物和10~30%聚乳酸-羟基乙酸共聚物混合均匀,加入原料重量0.1-0.4%碳酸二甲酯,在温度为130-140℃、转速为12-15rpm下加热搅拌挤压,降温制成聚合物核心,该步骤不破坏各成分的结构,仍能保持其活性,聚乳酸-羟基乙酸共聚物和碳酸二甲酯的加入能够保护活性物质,缓释时有助于活性物质发挥作用;
聚合物套制备:往剩余聚乳酸-羟基乙酸共聚物中加入原料重量0.1-0.3%的三乙醇胺和0.2-0.5%的尼泊金乙酯,在温度为140-150℃、转速为2-6rpm下加热搅拌挤压,切割挤成空心开口方形,该步骤所得聚合物套具有缓释时间长、对生物刺激小的特点,在水存在下通过酯键的水解而降解,水解产物对乌贼无不良影响;
催熟专有制剂制备:将聚合物核心置于空心开口方形套中,在25kGy以上进行γ-照射,即得催熟专有制剂,该制备方法可使催熟专有制剂释放活性延长,对减少突释、提高包封率、保留活性均具有重要意义,具有较大的市场潜力,该制备得到的催熟专有制剂具有较高的药物稳定性,药效高,具有缓释或控释性能,延长药效的作用时间,以促进卵细胞和精子最后成熟,达到促进乌贼性成熟的目的。
与现有技术相比,本发明的优点在于:本发明催熟方法是将催熟专有试剂植入白斑乌贼眼窝窦内,达到催熟的目的,这种人工催熟方法具有能快速催熟、安全无害、操作简单的优势,使得乌贼不必再依靠其自然繁殖和产卵;本发明催熟专有试剂具有较高的药物稳定性,药效高,具有缓释或控释性能,延长药效的作用时间,以促进卵细胞和精子最后成熟,达到促进乌贼性成熟的目的;该催熟专有制剂释放活性延长,对减少突释、提高包封率、保留活性均具有重要意义,具有较大的市场潜力。
具体实施方式
下面通过实施例对本发明方案作进一步说明:
实施例1:
一种白斑乌贼催熟方法,其具体步骤为:
采集性成熟白斑乌贼成体;将白斑乌贼放入含1.7-2.0% MgCl2和0.3-0.6%异丁香酚的海水中浸泡100-120s,进行活体浸泡麻醉;用灭菌的解剖刀剖开乌贼眼下的眼窝窦,将催熟专有试剂植入眼窝窦,植入量为70-80ug/g,采用外敷愈合剂涂覆在伤口上,使伤口愈合。上述外敷愈合剂的成分及其重量份为:尿囊素18-22份、海藻酸盐3-7份、桐油0.7-1.3份份、维生素C 0.3-0.5份、蜂蜜12-15份。
一种白斑乌贼催熟专有试剂,该催熟试剂为缓释包埋剂,催熟专有试剂的成分及其重量份为:血清素0.06-0.08份、绒毛膜促性腺激素0.01-0.012份、促黄体生成素释放素类似物0.13-0.15份、脑垂体器提取物0.004-0.006份、花生四烯酸0.011-0.013份、聚乳酸-羟基乙酸共聚物1-2份。
一种白斑乌贼催熟专有试剂,其制备方法为:
1)核心制备:将血清素、绒毛膜促性腺激素、促黄体生成素释放素类似物、鱼性腺提取物、脑垂体器提取物和10~30%聚乳酸-羟基乙酸共聚物混合均匀,加入原料重量0.1-0.4%碳酸二甲酯,在温度为130-140℃、转速为12-15rpm下加热搅拌挤压,降温制成聚合物核心;
2)聚合物套制备:往剩余聚乳酸-羟基乙酸共聚物中加入原料重量0.1-0.3%的三乙醇胺和0.2-0.5%的尼泊金乙酯,在温度为140-150℃、转速为2-6rpm下加热搅拌挤压,切割挤成空心开口方形;
3)催熟专有制剂制备:将聚合物核心置于空心开口方形套中,在25kGy以上进行γ-照射,即得催熟专有制剂。
实施例2:
一种白斑乌贼催熟方法,其具体步骤为:
采集性成熟白斑乌贼成体;将白斑乌贼放入含1.7% MgCl2和0.4%异丁香酚的海水中浸泡120s,进行活体浸泡麻醉;用灭菌的解剖刀剖开乌贼眼下的眼窝窦,将催熟专有试剂植入眼窝窦,植入量为80ug/g,采用外敷愈合剂涂覆在伤口上,使伤口愈合。上述外敷愈合剂的成分及其重量份为:尿囊素22份、海藻酸盐4份、桐油1.1份份、维生素C 0.35份、蜂蜜14份,维生素C中L-抗坏血酸和D-抗坏血酸的重量比为100:0.38-0.42,该D-抗坏血酸的加入可提高外敷愈合剂的活性,更易于被机体吸收,利于细胞的再生,促使伤口愈合,也能增强机体抵抗力和活力,防止伤口感染,最大限度地降低对乌贼的伤害。
一种白斑乌贼催熟专有试剂,该催熟试剂为缓释包埋剂,催熟专有试剂的成分及其重量份为:血清素0.08份、绒毛膜促性腺激素0.01份、促黄体生成素释放素类似物0.15份、脑垂体器提取物0.004份、花生四烯酸0.013份、聚乳酸-羟基乙酸共聚物1.7份。
一种白斑乌贼催熟专有试剂,其制备方法为:
1)核心制备:将血清素、绒毛膜促性腺激素、促黄体生成素释放素类似物、鱼性腺提取物、脑垂体器提取物和30%聚乳酸-羟基乙酸共聚物混合均匀,加入原料重量0.1%碳酸二甲酯,在温度为140℃、转速为15rpm下加热搅拌挤压,降温制成聚合物核心;
2)聚合物套制备:往剩余聚乳酸-羟基乙酸共聚物中加入原料重量0.3%的三乙醇胺和0.2%的尼泊金乙酯,在温度为150℃、转速为2rpm下加热搅拌挤压,切割挤成空心开口方形;
3)催熟专有制剂制备:将聚合物核心置于空心开口方形套中,在25kGy以上进行γ-照射,即得催熟专有制剂。
实施例3:
一种白斑乌贼催熟方法,其具体步骤为:
采集性成熟白斑乌贼成体;将白斑乌贼放入含1.8% MgCl2和0.5%异丁香酚的海水中浸泡110s,进行活体浸泡麻醉;用灭菌的解剖刀剖开乌贼眼下的眼窝窦,将催熟专有试剂植入眼窝窦,植入量为75ug/g,采用外敷愈合剂涂覆在伤口上,使伤口愈合。上述外敷愈合剂的成分及其重量份为:尿囊素20份、海藻酸盐5份、桐油1.0份份、维生素C 0.4份、蜂蜜13份。
一种白斑乌贼催熟专有试剂,该催熟试剂为缓释包埋剂,催熟专有试剂的成分及其重量份为:血清素0.078份、绒毛膜促性腺激素0.011份、促黄体生成素释放素类似物0.14份、脑垂体器提取物0.005份、花生四烯酸0.012份、聚乳酸-羟基乙酸共聚物1.5份。
一种白斑乌贼催熟专有试剂,其制备方法为:
1)核心制备:将血清素、绒毛膜促性腺激素、促黄体生成素释放素类似物、鱼性腺提取物、脑垂体器提取物和20%聚乳酸-羟基乙酸共聚物混合均匀,加入原料重量0.2%碳酸二甲酯,在温度为135℃、转速为14rpm下加热搅拌挤压,降温制成聚合物核心;
2)聚合物套制备:往剩余聚乳酸-羟基乙酸共聚物中加入原料重量0.2%的三乙醇胺和0.4%的尼泊金乙酯,在温度为145℃、转速为4rpm下加热搅拌挤压,切割挤成空心开口方形;
3)催熟专有制剂制备:将聚合物核心置于空心开口方形套中,在25kGy以上进行γ-照射,即得催熟专有制剂。
本发明的操作步骤中的常规操作为本领域技术人员所熟知,在此不进行赘述。
以上所述的实施例对本发明的技术方案进行了详细说明,应理解的是以上所述仅为本发明的具体实施例,并不用于限制本发明,凡在本发明的原则范围内所做的任何修改、补充或类似方式替代等,均应包含在本发明的保护范围之内。
Claims (8)
1.一种白斑乌贼催熟方法,其特征在于:所述催熟方法为:将性成熟白斑乌贼成体麻醉,将催熟试剂的植入眼窝窦,伤口愈合。
2. 根据权利要求1所述的一种白斑乌贼催熟方法,其特征在于:所述麻醉为:将白斑乌贼放入含1.7-2.0% MgCl2和0.3-0.6%异丁香酚的海水中,麻醉浸泡100-120s。
3.根据权利要求1所述的一种白斑乌贼催熟方法,其特征在于:所述植入用灭菌的解剖刀剖开乌贼眼下的眼窝窦,将催熟试剂的植入眼窝窦。
4.根据权利要求1所述的一种白斑乌贼催熟方法,其特征在于:所述催熟试剂植入量为70-80ug/g。
5. 根据权利要求1所述的一种白斑乌贼催熟方法,其特征在于:所述伤口愈合采用外敷愈合剂涂覆在伤口上,所述外敷愈合剂的成分及其重量份为:尿囊素18-22份、海藻酸盐3-7份、桐油0.7-1.3份份、维生素C 0.3-0.5份、蜂蜜12-15份。
6.一种白斑乌贼催熟专有试剂,其特征在于:所述催熟试剂为缓释包埋剂。
7.根据权利要求6所述的一种白斑乌贼催熟专有试剂,其特征在于:所述催熟专有试剂的成分及其重量份为:血清素0.06-0.08份、绒毛膜促性腺激素0.01-0.012份、促黄体生成素释放素类似物0.13-0.15份、脑垂体器提取物0.004-0.006份、花生四烯酸0.011-0.013份、聚乳酸-羟基乙酸共聚物1-2份。
8.根据权利要求6所述的一种白斑乌贼催熟专有试剂,其特征在于:所述试剂的制备方法为:
1)核心制备:将血清素、绒毛膜促性腺激素、促黄体生成素释放素类似物、鱼性腺提取物、脑垂体器提取物和10~30%聚乳酸-羟基乙酸共聚物混合均匀,加入碳酸二甲酯,加热搅拌挤压,降温制成聚合物核心;
2)聚合物套制备:往剩余聚乳酸-羟基乙酸共聚物中加入三乙醇胺和尼泊金乙酯,加热搅拌挤压,并切割挤成空心开口方形;
3)专有制剂制备:将聚合物核心置于空心开口方形套中,在25kGy以上进行γ-照射,即得催熟专有试剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711072006.XA CN107810887A (zh) | 2017-11-03 | 2017-11-03 | 一种白斑乌贼催熟方法及专有试剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711072006.XA CN107810887A (zh) | 2017-11-03 | 2017-11-03 | 一种白斑乌贼催熟方法及专有试剂 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107810887A true CN107810887A (zh) | 2018-03-20 |
Family
ID=61603684
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711072006.XA Pending CN107810887A (zh) | 2017-11-03 | 2017-11-03 | 一种白斑乌贼催熟方法及专有试剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107810887A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109874711A (zh) * | 2019-04-18 | 2019-06-14 | 中国水产科学研究院黄海水产研究所 | 一种提高刺参种参排放率和排卵量的方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1784954A (zh) * | 2004-12-10 | 2006-06-14 | 中国水产科学研究院东海水产研究所 | 黄鲷人工催产的方法 |
CN103444608A (zh) * | 2013-09-12 | 2013-12-18 | 中国水产科学研究院黄海水产研究所 | 一种狼鳗亲体的生殖调控方法 |
CN106719178A (zh) * | 2016-12-05 | 2017-05-31 | 浙江海洋大学 | 一种头足类的人工促熟方法 |
-
2017
- 2017-11-03 CN CN201711072006.XA patent/CN107810887A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1784954A (zh) * | 2004-12-10 | 2006-06-14 | 中国水产科学研究院东海水产研究所 | 黄鲷人工催产的方法 |
CN103444608A (zh) * | 2013-09-12 | 2013-12-18 | 中国水产科学研究院黄海水产研究所 | 一种狼鳗亲体的生殖调控方法 |
CN106719178A (zh) * | 2016-12-05 | 2017-05-31 | 浙江海洋大学 | 一种头足类的人工促熟方法 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109874711A (zh) * | 2019-04-18 | 2019-06-14 | 中国水产科学研究院黄海水产研究所 | 一种提高刺参种参排放率和排卵量的方法 |
CN109874711B (zh) * | 2019-04-18 | 2020-10-09 | 中国水产科学研究院黄海水产研究所 | 一种提高刺参种参排放率和排卵量的方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105075941B (zh) | 尖头塘鳢与云斑尖塘鳢杂交育种方法 | |
CN103478033B (zh) | 黄鳝的无公害养殖方法 | |
CN103493764A (zh) | 螃蟹的抗病毒养殖方法 | |
CN103563800A (zh) | 一种黄鳝、泥鳅网箱立体养殖方法 | |
CN102893936B (zh) | 大鳞副泥鳅苗种培育方法 | |
CN105660465A (zh) | 一种龙虾的人工育苗方法 | |
CN103392647A (zh) | 一种科学精确养殖黄鳝方法 | |
CN107396862A (zh) | 一种罗非鱼套养白对虾的养殖方法 | |
CN102960559A (zh) | 一种人工大规模饲养花绒寄甲的饲料及其配套繁育技术 | |
CN102017921A (zh) | 一种翘嘴鳜鱼与大眼鳜鱼杂交及养殖方法 | |
CN107242161A (zh) | 一种黑鲷鱼苗种培育技术 | |
CN107372301A (zh) | 一种促进甲鱼生长的养殖方法 | |
CN107810887A (zh) | 一种白斑乌贼催熟方法及专有试剂 | |
CN103843704A (zh) | 一种梭子蟹育苗的方法 | |
CN105660467A (zh) | 一种鲶鱼家庭小面积养殖的方法 | |
CN107996467A (zh) | 一种草鱼的饲养管理方法 | |
CN107372221A (zh) | 一种泥鳅的育苗方法 | |
CN106614158A (zh) | 一种医用水蛭高密度养殖方法 | |
CN105104294A (zh) | 一种甲鱼的饲养方法 | |
CN1806535A (zh) | 一种促进日本对虾卵巢成熟和产卵的方法 | |
CN103461252B (zh) | 胭脂鱼亲鱼培育与促熟方法 | |
CN101559060B (zh) | 防治鱼寄生甲壳动物病的药物及其制备方法与应用 | |
CN106386444A (zh) | 一种提高秋葵锌元素含量的无土栽培方法 | |
CN104472399B (zh) | 一种黄鳝种内杂交育种方法 | |
CN105432522A (zh) | 美国斑点叉尾鮰鱼的养殖方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180320 |
|
RJ01 | Rejection of invention patent application after publication |